益盛药业(002566) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was CNY 877,929,541.89, representing a 4.19% increase compared to CNY 842,589,907.04 in 2020[19] - The net profit attributable to shareholders for 2021 was CNY 96,020,349.90, a 19.94% increase from CNY 80,060,085.80 in 2020[19] - The net profit after deducting non-recurring gains and losses was CNY 83,970,880.18, up 27.72% from CNY 65,746,181.53 in 2020[19] - The basic earnings per share for 2021 was CNY 0.2901, reflecting a 19.93% increase from CNY 0.2419 in 2020[19] - The total assets at the end of 2021 were CNY 2,864,366,655.13, a 2.44% increase from CNY 2,796,099,005.75 at the end of 2020[19] - The net assets attributable to shareholders at the end of 2021 were CNY 2,081,809,739.53, up 4.31% from CNY 1,995,717,937.63 at the end of 2020[19] - The net cash flow from operating activities for 2021 was CNY 215,100,714.73, a 5.69% increase from CNY 203,514,966.83 in 2020[19] - The weighted average return on equity for 2021 was 4.72%, an increase from 4.08% in 2020[19] Product Development and Innovation - The company has developed a complete industrial chain for ginseng, expanding from pharmaceutical production to health products and cosmetics[31] - The company holds 117 product varieties and has 49 products listed in the National Basic Medical Insurance Drug Catalog[31] - The company has cultivated over 10,000 acres of organic non-forest ginseng, recognized as a protected ecological origin product[32] - The company has received 14 patents and established a comprehensive planting technology system for ginseng cultivation[32] - The company completed the development and filing of 30 health food products, launching 5 new products during the reporting period[42] - The company launched 14 new cosmetic products and enhanced its online sales channels, including live streaming sales[44] Market and Sales Performance - The pharmaceutical sector contributed ¥665,013,635.04, accounting for 75.75% of total revenue, with a year-on-year growth of 3.46%[46] - The online direct sales model saw a significant decline of 63.76%, dropping to ¥11,223,826.07 from ¥30,973,020.78 in the previous year[46] - The company sold 37,040,371 boxes in the pharmaceutical sector, an increase of 3.27% from 35,868,297 boxes in 2020[49] - The revenue from the cosmetics sector was ¥116,288,065.52, with a slight increase of 0.28% year-on-year[46] Research and Development - Research and development expenses increased by 32.98% to ¥20,892,630.06, primarily due to increased clinical trial costs[58] - The total R&D investment reached ¥37,584,947.77, a 13.12% increase compared to the previous year, with R&D expenses accounting for 4.28% of operating revenue[60] - The company has ongoing clinical research projects aimed at enhancing product competitiveness in the market[59] Corporate Governance and Management - The company adheres to strict governance practices, ensuring compliance with relevant laws and regulations while maintaining effective communication with shareholders[86] - The company has established a performance-based incentive and evaluation system for its senior management to align compensation with company performance[87] - The company has a robust organizational structure, with independent operation of the shareholders' meeting, board of directors, and supervisory board[91] - The company has established a performance appraisal system linking employee salaries to company performance and individual contributions[119] Social Responsibility and Environmental Compliance - The company actively engaged in social responsibility initiatives during the COVID-19 pandemic, including donations and compliance with information disclosure[45] - The company emphasizes environmental protection and has integrated energy conservation and emission reduction into its key agenda[137] - The company has not faced any administrative penalties for environmental issues during the reporting period, demonstrating compliance with environmental regulations[133] Future Outlook and Strategic Plans - The company plans to strengthen its marketing network and optimize its marketing organization to enhance overall performance in 2022[78] - The company aims to leverage existing resources through contract manufacturing to transition products from reserve to market-ready[78] - The company plans to continue expanding its market presence and product offerings in the future[114] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 100 million yuan allocated for potential deals[104] Shareholder Structure and Transparency - The company’s shareholder structure remained stable, with no significant changes in asset and liability structure reported[173] - The largest shareholder, Zhang Yisheng, holds 39.08% of the shares, totaling 129,348,530 shares[175] - The company has a total of 132,792,449 shares held by its directors and senior management, with some changes in shareholding during the reporting period[95] - The company is implementing a rectification plan to resolve the proxy shareholding issue, aiming for a swift resolution[178]